drug · small molecule
BOSENTAN
Marketedupdated 3mo agoby $NSRX Nasus Pharma Ltd🔗 ChEMBL
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 5Small molecule drug with a maximum clinical stage of Approval (across all indications), with 5 approved and 23 investigational indications.
targets
Endothelin receptor, ET-A/ET-B
all catalysts(21)
approval · 21
Apr 26, 2019
approval
$NSRX2.7000-1.82%
BOSENTAN — FDA approval
BOSENTAN
→
Apr 26, 2019
approval
BOSENTAN — FDA approval
BOSENTAN
→
Nov 4, 2019
approval
BOSENTAN — FDA approval
BOSENTAN
→
Apr 29, 2022
approval
$NSRX2.7000-1.82%
BOSENTAN — FDA approval
BOSENTAN
→
Apr 29, 2022
approval
BOSENTAN — FDA approval
BOSENTAN
→
Sep 17, 2024
approval
$NSRX2.7000-1.82%
BOSENTAN — FDA approval
BOSENTAN
→
Sep 17, 2024
approval
BOSENTAN — FDA approval
BOSENTAN
→
Jan 23, 2025
approval
BOSENTAN — FDA approval
BOSENTAN
→
Jan 23, 2025
approval
BOSENTAN — FDA approval
BOSENTAN
→
Feb 5, 2025
approval
$NSRX2.7000-1.82%
BOSENTAN — FDA approval
BOSENTAN
→
Feb 21, 2025
approval
$NSRX2.7000-1.82%
BOSENTAN — FDA approval
BOSENTAN
→
Feb 21, 2025
approval
$NSRX2.7000-1.82%
BOSENTAN — FDA approval
BOSENTAN
→
Feb 21, 2025
approval
BOSENTAN — FDA approval
BOSENTAN
→
Nov 5, 2025
approval
$NSRX2.7000-1.82%
BOSENTAN — FDA approval
BOSENTAN
→
Nov 5, 2025
approval
BOSENTAN — FDA approval
BOSENTAN
→
Nov 5, 2025
approval
$NSRX2.7000-1.82%
BOSENTAN — FDA approval
BOSENTAN
→
Mar 3, 2026
approval
BOSENTAN — FDA approval
BOSENTAN
→
Mar 3, 2026
approval
$NSRX2.7000-1.82%
BOSENTAN — FDA approval
BOSENTAN
→
Mar 3, 2026
approval
$NSRX2.7000-1.82%
BOSENTAN — FDA approval
BOSENTAN
→
Apr 14, 2026
approval
BOSENTAN — FDA approval
BOSENTAN
→
Apr 14, 2026
approval
BOSENTAN — FDA approval
BOSENTAN
→
Trials studying BOSENTAN
- phase2Effect of Bosentan in Patients With Metastatic Melanoma Treated With Dacarbazine (DTIC)
- phase1A Study in Healthy Men to Test Whether Bosentan Influences the Amount of BI 425809 in the Blood
- phase2Preventive Effects of Bosentan on the Systemic Cardiovascular Consequence of Sleep Apnea
- phase1A Study in Healthy Men to Test How Bosentan Influences the Amount of Nerandomilast in the Blood
- phase1Study to Evaluate the Effect of Bosentan on the Pharmacokinetics of Lurbinectedin in Patients With Advanced Solid Tumors
- phase3FUTURE 3 Study Extension
- phase3Open Label Extension Study in Patients With Idiopathic Pulmonary Fibrosis Who Completed Protocol AC-052-321/ BUILD 3 / NCT00391443
- phase3Efficacy and Safety of Bosentan in Sickle Cell Disease (SCD) Patients With Pulmonary Arterial Hypertension (PAH)
Patent cliff
source: FDA Orange Bookfirst barrier falls
Dec 28, 2027
~1.4 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (2)
- Dec 28, 2027formulationUS 79599451.4y
- May 15, 2026formulationUS 8309126
FDA exclusivities (1)
- Feb 14, 2026PCPC
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 1h ago
Found something off?
comments(0)
5-min edit window · permanent after that